Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of mRNA-Based Multivalent Seasonal Influenza Vaccine Candidates in Adults
NCT07121192Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2025
- Primary completion
- May 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GSKVX000000077430, influenza messenger RNA formulation B in influenza, sponsored by GSK. Started Aug 2025; status: completed.
02
Drugs
GSKVX000000077430influenza messenger RNA formulation B
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07121192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07121192.